246 related articles for article (PubMed ID: 28606094)
1. What is the impact of PCSK9 rs505151 and rs11591147 polymorphisms on serum lipids level and cardiovascular risk: a meta-analysis.
Qiu C; Zeng P; Li X; Zhang Z; Pan B; Peng ZYF; Li Y; Ma Y; Leng Y; Chen R
Lipids Health Dis; 2017 Jun; 16(1):111. PubMed ID: 28606094
[TBL] [Abstract][Full Text] [Related]
2. The associations between proprotein convertase subtilisin/kexin type 9 E670G polymorphism and the risk of coronary artery disease and serum lipid levels: a meta-analysis.
Cai G; Zhang B; Shi G; Weng W; Ma C; Song Y; Zhang J
Lipids Health Dis; 2015 Nov; 14():149. PubMed ID: 26576960
[TBL] [Abstract][Full Text] [Related]
3. Characterization of LDLR rs5925 and PCSK9 rs505151 genetic variants frequencies in healthy subjects from northern Chile: Influence on plasma lipid levels.
Rojas C; Ramírez H; Salazar LA; Kalergis AM; Gálvez AS; Escobar-Vera J
J Clin Lab Anal; 2019 Nov; 33(9):e23001. PubMed ID: 31441123
[TBL] [Abstract][Full Text] [Related]
4. Low LDL Cholesterol by PCSK9 Variation Reduces Cardiovascular Mortality.
Benn M; Tybjærg-Hansen A; Nordestgaard BG
J Am Coll Cardiol; 2019 Jun; 73(24):3102-3114. PubMed ID: 31221259
[TBL] [Abstract][Full Text] [Related]
5. Integrative mutation, haplotype and G × G interaction evidence connects ABGL4, LRP8 and PCSK9 genes to cardiometabolic risk.
Guo T; Yin RX; Yao LM; Huang F; Pan L; Lin WX; Yang DZ; Pan SL
Sci Rep; 2016 Nov; 6():37375. PubMed ID: 27853278
[TBL] [Abstract][Full Text] [Related]
6. PCSK9 genetic (rs11591147) and epigenetic (DNA methylation) modifications associated with PCSK9 expression and serum proteins in CAD patients.
Shyamala N; Gundapaneni KK; Galimudi RK; Tupurani MA; Padala C; Puranam K; Kupsal K; Kummari R; Gantala SR; Nallamala KR; Sahu SK; Hanumanth SR
J Gene Med; 2021 Aug; 23(8):e3346. PubMed ID: 33885177
[TBL] [Abstract][Full Text] [Related]
7. The association of the PCSK9 rs562556 polymorphism with serum lipids level: a meta-analysis.
Chuan J; Qian Z; Zhang Y; Tong R; Peng M
Lipids Health Dis; 2019 Apr; 18(1):105. PubMed ID: 31036026
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of PCSK9 levels and its genetic polymorphisms in women with polycystic ovary syndrome.
Xavier LB; Sóter MO; Sales MF; Oliveira DK; Reis HJ; Candido AL; Reis FM; Silva IO; Gomes KB; Ferreira CN
Gene; 2018 Feb; 644():129-136. PubMed ID: 29109005
[TBL] [Abstract][Full Text] [Related]
9. Association study of
Devi K; Bhargave A; Ahmad I; Yadav A; Gupta R
Ann Hum Biol; 2023 Feb; 50(1):56-62. PubMed ID: 36695028
[TBL] [Abstract][Full Text] [Related]
10. The Impact of
Wang J; Li S; Ren Y; Wang G; Li W
J Integr Neurosci; 2024 Mar; 23(3):62. PubMed ID: 38538222
[TBL] [Abstract][Full Text] [Related]
11. Effect of the PCSK9 R46L genetic variant on plasma insulin and glucose levels, risk of diabetes mellitus and cardiovascular disease: A meta-analysis.
Liu S; Wan J; Wang D; Yang Y; Fang J; Luo T; Liang D; Hu J; Hou J; Wang P
Nutr Metab Cardiovasc Dis; 2024 Jun; 34(6):1339-1351. PubMed ID: 38734541
[TBL] [Abstract][Full Text] [Related]
12. R46L polymorphism in the PCSK9 gene: Relationship to lipid levels, subclinical vascular disease, and erectile dysfunction.
Mostaza JM; Lahoz C; Salinero-Fort MA; de Dios O; Castillo E; González-Alegre T; García-Iglesias F; Estirado E; Laguna F; Sabín C; López S; Cornejo V; de Burgos C; Sanchez V; Garcés C;
J Clin Lipidol; 2018; 12(4):1039-1046.e3. PubMed ID: 29773421
[TBL] [Abstract][Full Text] [Related]
13. Serum PCSK9 levels, but not PCSK9 polymorphisms, are associated with CAD risk and lipid profiles in southern Chinese Han population.
Cai G; Yu L; Huang Z; Li L; Fu X
Lipids Health Dis; 2018 Sep; 17(1):213. PubMed ID: 30205809
[TBL] [Abstract][Full Text] [Related]
14.
Mohamed SH; Hassaan MMM; Ibrahim BA; Sabbah NA
Genet Test Mol Biomarkers; 2021 Sep; 25(9):615-623. PubMed ID: 34550777
[No Abstract] [Full Text] [Related]
15. PCSK9 R46L, lower LDL, and cardiovascular disease risk in familial hypercholesterolemia: a cross-sectional cohort study.
Saavedra YG; Dufour R; Davignon J; Baass A
Arterioscler Thromb Vasc Biol; 2014 Dec; 34(12):2700-5. PubMed ID: 25278291
[TBL] [Abstract][Full Text] [Related]
16. Association between the DOCK7, PCSK9 and GALNT2 Gene Polymorphisms and Serum Lipid levels.
Guo T; Yin RX; Huang F; Yao LM; Lin WX; Pan SL
Sci Rep; 2016 Jan; 6():19079. PubMed ID: 26744084
[TBL] [Abstract][Full Text] [Related]
17. The Influence of OLR1 and PCSK9 Gene Polymorphisms on Ischemic Stroke: Evidence from a Meta-Analysis.
Au A; Griffiths LR; Cheng KK; Wee Kooi C; Irene L; Keat Wei L
Sci Rep; 2015 Dec; 5():18224. PubMed ID: 26666837
[TBL] [Abstract][Full Text] [Related]
18. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.
Bergeron N; Phan BA; Ding Y; Fong A; Krauss RM
Circulation; 2015 Oct; 132(17):1648-66. PubMed ID: 26503748
[TBL] [Abstract][Full Text] [Related]
19. Associations of the APOB rs693 and rs17240441 polymorphisms with plasma APOB and lipid levels: a meta-analysis.
Niu C; Luo Z; Yu L; Yang Y; Chen Y; Luo X; Lai F; Song Y
Lipids Health Dis; 2017 Sep; 16(1):166. PubMed ID: 28874158
[TBL] [Abstract][Full Text] [Related]
20. Prediction of cardiovascular events with levels of proprotein convertase subtilisin/kexin type 9: A systematic review and meta-analysis.
Vlachopoulos C; Terentes-Printzios D; Georgiopoulos G; Skoumas I; Koutagiar I; Ioakeimidis N; Stefanadis C; Tousoulis D
Atherosclerosis; 2016 Sep; 252():50-60. PubMed ID: 27501130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
